Mustang Bio Secures $2M NIH Grant For CAR T Cell Therapy Development

by Vandana Singh, Benzinga Editor

November 1, 2021 10:19 AM | 1 min read | Make a Comment

Mustang Bio Inc MBIO has been awarded a grant of approximately $2 million from the National Cancer Institute of the National Institutes of Health (NIH).
The two-year award will partially fund the Phase 1 trial to assess the safety, tolerability, and efficacy of MB-106 for relapsed or refractory B-cell non-Hodgkin lymphomas or chronic lymphocytic leukemia.
MB-106 is a CD20-targeted, autologous CAR T cell therapy.
Related: Mustang Bio's CAR T Cell Therapy Achieves 93% ORR, 67% CR In Mid-Stage Leukemia Trial.
In addition, the Office for Human Research Protections has approved Federalwide Assurance for Mustang's research for the protection of human subjects in research.
Price Action: MBIO shares are up 3.98% at $2.32 during the market session on the last check Monday.